5-羟色胺能
血清素
精神分裂症(面向对象编程)
医学
精神病
病理生理学
联想(心理学)
神经科学
心理学
精神科
内科学
精神分裂症谱
神经递质
内分泌学
血清素拮抗剂
5-羟色胺受体
探索性分析
萧条(经济学)
中枢神经系统
作者
Martin Osugo,Thomas Whitehurst,David Erritzøe,Richard Carr,Abhishekh Hulegar Ashok,Lucia Maccioni,Ellis Chika Onwordi,Grazia Rutigliano,Nikola Rahaman,Atheeshaan Arumuham,Antonio de Marvao,Roger N. Gunn,Eugenii A. Rabiner,Tiago Reis Marques,Mattia Veronese,Oliver David Howes
出处
期刊:JAMA Psychiatry
[American Medical Association]
日期:2025-12-10
卷期号:83 (2): 185-185
被引量:11
标识
DOI:10.1001/jamapsychiatry.2025.3430
摘要
Importance: The involvement of the serotonin system in the pathophysiology of schizophrenia has been proposed for over 60 years, but there has been no prior study to test if there is altered serotonin release in vivo in schizophrenia (to the authors' knowledge). Objective: To investigate serotonin release in vivo in schizophrenia and its association with negative symptoms. It was hypothesized a priori that frontal cortex serotonin release capacity would be lower in schizophrenia compared with healthy controls and that this would be associated with more severe baseline negative symptoms. Design, Setting, and Participants: This was a single-center case-control neuroimaging study conducted in London, UK. All participants had dynamic 90-minute [11C]Cimbi-36 positron emission tomography (PET) scans at baseline and 3 hours after oral administration of d-amphetamine 0.5mg/kg. Data were collected between 2015 and 2024. Participants included stable adult outpatients with DSM-5 schizophrenia (antipsychotic free or taking antipsychotics with negligible affinity for 5-hydroxytryptamine receptor 2A [5-HT2A] receptors) and healthy controls matched for age, sex, and body mass index. Main Outcomes and Measures: The primary neuroimaging outcome was the group difference in serotonin release capacity, prespecified as the percentage change in frontal cortex [11C]Cimbi-36 binding potential between the baseline and d-amphetamine scans. Results: A total of 54 individuals were included, 26 with DSM-5 schizophrenia (mean [SD] age, 33.3 [9.1] years, 16 male [62%]; 21 not taking antipsychotic medication [81%]) and 28 healthy controls (mean [SD] age, 32.0 [9.5] years, 19 male [68%]). Frontal cortex serotonin release was significantly greater in the group with schizophrenia compared with healthy controls (18.0%; 95% CI, 2.5%-33.6%; P = .02; Cohen d = 0.69). In schizophrenia, greater frontal cortex serotonin release was correlated with more severe baseline negative symptoms (Brief Negative Symptom Scale: Pearson r = 0.42; P = .04) and poorer functioning (Social Functioning Scale: Pearson r = -0.42; P = .04). Exploratory analyses showed significantly greater frontal cortex serotonin release in deficit schizophrenia, characterized by primary and enduring negative symptoms, compared with healthy controls (mean difference = 32.3%; FDR-corrected P value = 0.001; Cohen d = 1.10) and nondeficit schizophrenia (mean difference = 28.9%; FDR-corrected P value = 0.004; Cohen d = 0.89). These findings were all replicated in 21 individuals with schizophrenia not taking antipsychotic medication. Baseline cortical [11C]Cimbi-36 binding (indexing baseline cortical 5-HT2A receptor levels) was unaltered in schizophrenia. Conclusions and Relevance: This case-control study found that serotonergic dysfunction in the pathophysiology of schizophrenia was associated with negative symptoms, suggesting the regulation of serotonin release as a target to treat negative symptoms. Results of the exploratory analysis suggest particularly marked serotonergic dysfunction in the subgroup with deficit schizophrenia.
科研通智能强力驱动
Strongly Powered by AbleSci AI